207 related articles for article (PubMed ID: 33128485)
41. Memory T cells persisting in the brain following MCMV infection induce long-term microglial activation via interferon-γ.
Mutnal MB; Hu S; Little MR; Lokensgard JR
J Neurovirol; 2011 Oct; 17(5):424-37. PubMed ID: 21800103
[TBL] [Abstract][Full Text] [Related]
42. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
43. PD-L1 enhances CNS inflammation and infarct volume following experimental stroke in mice in opposition to PD-1.
Bodhankar S; Chen Y; Vandenbark AA; Murphy SJ; Offner H
J Neuroinflammation; 2013 Sep; 10():111. PubMed ID: 24015822
[TBL] [Abstract][Full Text] [Related]
44. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis.
Chang K; Svabek C; Vazquez-Guillamet C; Sato B; Rasche D; Wilson S; Robbins P; Ulbrandt N; Suzich J; Green J; Patera AC; Blair W; Krishnan S; Hotchkiss R
Crit Care; 2014 Jan; 18(1):R3. PubMed ID: 24387680
[TBL] [Abstract][Full Text] [Related]
45. PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.
Schreiner B; Bailey SL; Shin T; Chen L; Miller SD
Eur J Immunol; 2008 Oct; 38(10):2706-17. PubMed ID: 18825752
[TBL] [Abstract][Full Text] [Related]
46. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection.
Vezys V; Penaloza-MacMaster P; Barber DL; Ha SJ; Konieczny B; Freeman GJ; Mittler RS; Ahmed R
J Immunol; 2011 Aug; 187(4):1634-42. PubMed ID: 21742975
[TBL] [Abstract][Full Text] [Related]
47. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Durgan K; Ali M; Warner P; Latchman YE
Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
[TBL] [Abstract][Full Text] [Related]
48. CNS expression of B7-H1 regulates pro-inflammatory cytokine production and alters severity of Theiler's virus-induced demyelinating disease.
Duncan DS; Miller SD
PLoS One; 2011 Apr; 6(4):e18548. PubMed ID: 21494618
[TBL] [Abstract][Full Text] [Related]
49. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
50. PD-L1 blockade exhibits anti-tumor effect on brain metastasis by activating CD8
Masuda C; Morinaga M; Wakita D; Yorozu K; Kurasawa M; Sugimoto M; Kondoh O
Clin Exp Metastasis; 2022 Apr; 39(2):335-344. PubMed ID: 34797455
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 Checkpoint Inhibition Narrows the Antigen-Specific T Cell Receptor Repertoire in Chronic Lymphocytic Choriomeningitis Virus Infection.
Klein S; Ghersi D; Manns MP; Prinz I; Cornberg M; Kraft ARM
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641478
[TBL] [Abstract][Full Text] [Related]
52. PD-1/PD-L1 blockade can enhance HIV-1 Gag-specific T cell immunity elicited by dendritic cell-directed lentiviral vaccines.
Dai B; Xiao L; Bryson PD; Fang J; Wang P
Mol Ther; 2012 Sep; 20(9):1800-9. PubMed ID: 22588271
[TBL] [Abstract][Full Text] [Related]
53. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
54. A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody.
Lee EJ; Jang GY; Lee SE; Lee JW; Han HD; Park YM; Kang TH
Immunol Lett; 2021 Dec; 240():137-148. PubMed ID: 34710507
[TBL] [Abstract][Full Text] [Related]
55. Prediction of PD-L1 inhibition effects for HIV-infected individuals.
Zheltkova V; Argilaguet J; Peligero C; Bocharov G; Meyerhans A
PLoS Comput Biol; 2019 Nov; 15(11):e1007401. PubMed ID: 31693657
[TBL] [Abstract][Full Text] [Related]
56. Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.
Pilon-Thomas S; Mackay A; Vohra N; Mulé JJ
J Immunol; 2010 Apr; 184(7):3442-9. PubMed ID: 20194714
[TBL] [Abstract][Full Text] [Related]
57. A potential new pathway for PD-L1 costimulation of the CD8-T cell response to Listeria monocytogenes infection.
Xu D; Fu HH; Obar JJ; Park JJ; Tamada K; Yagita H; Lefrançois L
PLoS One; 2013; 8(2):e56539. PubMed ID: 23409193
[TBL] [Abstract][Full Text] [Related]
58. Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Zhou Q; Munger ME; Highfill SL; Tolar J; Weigel BJ; Riddle M; Sharpe AH; Vallera DA; Azuma M; Levine BL; June CH; Murphy WJ; Munn DH; Blazar BR
Blood; 2010 Oct; 116(14):2484-93. PubMed ID: 20570856
[TBL] [Abstract][Full Text] [Related]
59. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
[TBL] [Abstract][Full Text] [Related]
60. Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
Goldberg MV; Maris CH; Hipkiss EL; Flies AS; Zhen L; Tuder RM; Grosso JF; Harris TJ; Getnet D; Whartenby KA; Brockstedt DG; Dubensky TW; Chen L; Pardoll DM; Drake CG
Blood; 2007 Jul; 110(1):186-92. PubMed ID: 17392506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
